S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
LON:ABZA

Abzena Share Forecast, Price & News

GBX 15.75
0.00 (0.00 %)
(As of 10/11/2018)
Add
Compare
Today's Range
15.75
15.75
50-Day Range
15.75
15.75
52-Week Range
6
33.70
Volume100 shs
Average Volume220,500 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ABZA News and Ratings via Email

Sign-up to receive the latest news and ratings for Abzena and its competitors with MarketBeat's FREE daily newsletter.


Abzena logo

About Abzena

Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging conjugation technology. In addition, it provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

Headlines

(LSE:ABZA)
June 6, 2021 |  fool.co.uk
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Abzena (LON:ABZA) Frequently Asked Questions

What stocks does MarketBeat like better than Abzena?

Wall Street analysts have given Abzena a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abzena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Abzena's key executives?

Abzena's management team includes the following people:
  • Dr. William John Edward Burt, CEO & Exec. Director (Age 50)
  • Prof. Sunil Shaunak, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D., Co-Founder
  • Prof. Steve Brocchini Ph.D., Co-Founder
  • Dr. Jim Mills, Sr. VP of Technical Operations

What other stocks do shareholders of Abzena own?

What is Abzena's stock symbol?

Abzena trades on the London Stock Exchange (LON) under the ticker symbol "ABZA."

How do I buy shares of Abzena?

Shares of ABZA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Abzena's stock price today?

One share of ABZA stock can currently be purchased for approximately GBX 15.75.

What is Abzena's official website?

The official website for Abzena is www.abzena.com.

Where are Abzena's headquarters?

How can I contact Abzena?

Abzena's mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company can be reached via phone at +44-1223-903498.


This page was last updated on 10/15/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.